Bionetix, ProQinase, and MercachemSyncom have announced that they will jointly develop a new AML drug, from target identification to clinical testing
Merck KGaAs 2017 Swiss cancer spin-out iOnctura SA has raised €15m to bring its PI3K? inhibitor and autotaxin inhibitor to the clinic.
Ministers from 72 countries came together at the Berlin Agriculture Ministers conference to discuss and adopt a joint communiqué on global trade. In it, the ministers agreed to strengthen rule-based free trade.
HepaRegeniX has raised €11m in a Series B. The biotech company will use the proceeds to bring its compound targeting chronic liver disease to the clinic.
Swiss food giant Nestlé will invest up to €1.68bn to support sustainable packaging solutions and to create a market for plastic-free or recycled alternatives.
mRNA cancer neoantigen specialist BioNTech AG is set to buy all shares of Neon Therapeutics, Inc. expanding its pipeline of neoantigen-targeting therapies and getting foothold in the US.
British researchers have identified several small molecule drugs that sensitized B cell cancers to chemotherapy and extended survival in mouse models.
Adaptimmune Therapeutics plc and Japanese Astellas Pharma, Inc. have signed a discovery partnership to develop off-the-shelf allogeneic T cell-based cancer therapies from stem cells.
Twelve years after Roches $6.8bn hostile takeover bid for Illumina, the companies have entered into a 15-year partnership to boost personalised NGS-based cancer testing.
Incyte Corp. has signed a global license agreement for commercialisation of Morphosys AGs anti-CD-19 programme tafasitamab.